. Author manuscript; available in PMC: 2009 Aug 17.

Published in final edited form as: Cancer Biol Ther. 2008 May 7;7(5):709–717. doi: 10.4161/cbt.7.5.5713

Table 1. IC₅₀ (nM) of CDDO and its derivatives in pediatric solid tumor cell lines.

Cell line	Type	RT-CES	CDDO-Me Colony forming	³H-thymidine	CDDO Colony forming	CDDO-Im Colony forming	CDDO-TFEA Colony forming	CDDO-EA Colony forming	CDDO-DE Colony forming
HUVEC	Umbilical vein endothelial cells	110
RD	Rhabdomyosarcoma	280
RH41		219
SA-OS	Osteosarcoma	300
U2-OS		415
RD-ES	Ewing's sarcoma	309
TC32		402
TC71		373
TC106			117	43	>200	37	95	195	125
CHP134	Neuroblastoma	201
IMR32		232
IMR5		610
LAN1		160	35	75	>200	35	85
LAN5		250
NB-EB		305
NB-1691		283	8	137	>200	5	125
SKNAS		418	115	76	>200	30	170	95	35
SKNSH		630
SKNBE2		273
SKNDZ		525
SKNFI		465
SY5Y		181
15N			25	30	25	5	35

IC₅₀ are determined by various methods: RT-CES, ³H-thymidine incorporations and colony forming assays. The following compounds were used: CDDO-Me, CDDO, CDDO-Im, CDDO-TFEA, CDDO-EA and CDDO-DE.

Table 1. IC50 (nM) of CDDO and its derivatives in pediatric solid tumor cell lines.

Table 1. IC₅₀ (nM) of CDDO and its derivatives in pediatric solid tumor cell lines.